MOLNUPIRAVIA EIDD 2801 CAS 2349386-89-4

Email: elainesun829@gmail.com   elaine@hbhons.com  whatsapp/ skype/ telegram：8617121822505 Wickr Me: elainematerial Signal: +447448531968 Threema: TXJWATEA Molnupiravia / EIDD-2801 / MK-4482 CAS 2349386-89-4 EIDD-2801 (Molnupiravir) CAS 2349386-89-4 For Pets Product Name: EIDD-2801 (Molnupiravir) Synonyms: ((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate;EIDD-2801(EIDD 2801);EIDD-2801;Tube994;Molnupiravir;Molnupiravir(MK-4482);Uridine, 4-oxime, 5'-(2-methylpropanoate);β-D-N4 hydroxycytidine-5'-isopropyl ester CAS: 2349386-89-4 MF: C13H19N3O7 MW: 329.31 EINECS: 604-604-1 Description EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4- hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broadspectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment. History Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS. EIDD-2801 was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-prot biotechnology company wholly owned by Emory University, and with partial funding support from the U.S. government. Since licensed by Ridgeback, all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck. Uses EIDD 2801 is an orally bioavailable broad-spectrum antiviral that inhibits SARS-CoV-2 and other multiple endemic, epidemic and bat coronavirus and has the potential for seasonal and pandemic influenza treatment. An isopropylester prodrug of the ribonucleoside analog of EIDD-1931 that exhibits anti-influenza virus and coronaviruses activities. Package: 1kg/bag,5kg/bag or 25kg/Hardboard drum or as your requirment 1KG : Double pharma-grade polybag inside,sealed Aluminum foil bag outside 5KG : Double pharma-grade polybag inside,Hardboard cartons outside 25KG: Double pharma-grade polybag inside,Hardboard drum outside Delivery: It will be delivery within 1-3 days after get the payment. By Air or Express. It's Door to Door and it will delivery it to you hand with custom clearance.